<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang C</submitter><funding>NIAMS NIH HHS</funding><pagination>eabj3859</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8780201</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(64)</volume><pubmed_abstract>NOD-like receptor (NLR), family pyrin domain containing 3 (NLRP3) assembles a protein complex known as the NLRP3 inflammasome upon sensing certain pathogen products or sterile danger signals. Gain-of-function mutations such as the D301N substitution in NLRP3, which cause its constitutive activation (NLRP3&lt;sup>CA&lt;/sup>) also results in inflammasome assembly. This inflammasome processes pro–interleukin-1 β (pro–IL-1β) and pro–IL-18 into bioactive IL-1β and IL-18, respectively, and cleaves gasdermin D (GSDMD). GSDMD amino-terminal fragments form plasma membrane pores that facilitate the secretion of IL-1β and IL-18 and lead to the inflammatory cell death pyroptosis. Accordingly, GSDMD inactivation results in negligible spontaneous inflammation in various experimental models such as in &lt;i>Nlrp3&lt;sup>CA/+&lt;/sup>&lt;/i> mice lacking GSDMD (&lt;i>Nlrp3&lt;sup>CA/+&lt;/sup>&lt;/i>;&lt;i>Gsdmd&lt;sup>−/−&lt;/sup>&lt;/i> mice). Here, we found that &lt;i>Nlrp3&lt;sup>CA/+&lt;/sup>&lt;/i>;&lt;i>Gsdmd&lt;sup>−/−&lt;/sup>&lt;/i> mice, when challenged with LPS or TNF-α, still secreted IL-1β and IL-18, indicating inflammasome activation independent of GSDMD. Accordingly, &lt;i>Gsdmd&lt;sup>−/−&lt;/sup>&lt;/i> macrophages failed to secrete IL-1β and undergo pyroptosis when briefly exposed to NLRP3 inflammasome activators but released these cytokines when persistently activated. Sustained NLRP3 inflammasome induced caspase-8/-3 and GSDME cleavage and IL-1β maturation in vitro in &lt;i>Gsdmd&lt;sup>−/−&lt;/sup>&lt;/i> macrophages. Thus, a salvage inflammatory pathway involving caspase-8/-3–GSDME was activated after NLRP3 activation when the canonical NLRP3-GSDMD signaling was blocked. Consistent with genetic data, the active metabolite of FDA-approved disulfiram CuET, which inhibited GSDMD and GSDME cleavage in macrophages, reduced the severe inflammation and tissue damage that occurred in the &lt;i>Nlrp3&lt;sup>CA/+&lt;/sup>&lt;/i> mice. Thus, NLRP3 inflammasome activation overwhelms the protection afforded by GSDMD deficiency, rewiring signaling cascades through mechanisms that include GSDME to propagate inflammation.</pubmed_abstract><journal>Science immunology</journal><pubmed_title>NLRP3 inflammasome activation triggers gasdermin D-independent inflammation.</pubmed_title><pmcid>PMC8780201</pmcid><funding_grant_id>R01 AR076758</funding_grant_id><funding_grant_id>R01 AR049192</funding_grant_id><funding_grant_id>R01 AR054326</funding_grant_id><funding_grant_id>R01 AR068972</funding_grant_id><funding_grant_id>R01 AR072623</funding_grant_id><pubmed_authors>Kanneganti TD</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Xiao J</pubmed_authors><pubmed_authors>Alippe Y</pubmed_authors><pubmed_authors>Xu C</pubmed_authors><pubmed_authors>Monahan JB</pubmed_authors><pubmed_authors>Yang T</pubmed_authors><pubmed_authors>Mbalaviele G</pubmed_authors><pubmed_authors>Lieberman J</pubmed_authors><pubmed_authors>Sun K</pubmed_authors><pubmed_authors>Abu-Amer Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>NLRP3 inflammasome activation triggers gasdermin D-independent inflammation.</name><description>NOD-like receptor (NLR), family pyrin domain containing 3 (NLRP3) assembles a protein complex known as the NLRP3 inflammasome upon sensing certain pathogen products or sterile danger signals. Gain-of-function mutations such as the D301N substitution in NLRP3, which cause its constitutive activation (NLRP3&lt;sup>CA&lt;/sup>) also results in inflammasome assembly. This inflammasome processes pro–interleukin-1 β (pro–IL-1β) and pro–IL-18 into bioactive IL-1β and IL-18, respectively, and cleaves gasdermin D (GSDMD). GSDMD amino-terminal fragments form plasma membrane pores that facilitate the secretion of IL-1β and IL-18 and lead to the inflammatory cell death pyroptosis. Accordingly, GSDMD inactivation results in negligible spontaneous inflammation in various experimental models such as in &lt;i>Nlrp3&lt;sup>CA/+&lt;/sup>&lt;/i> mice lacking GSDMD (&lt;i>Nlrp3&lt;sup>CA/+&lt;/sup>&lt;/i>;&lt;i>Gsdmd&lt;sup>−/−&lt;/sup>&lt;/i> mice). Here, we found that &lt;i>Nlrp3&lt;sup>CA/+&lt;/sup>&lt;/i>;&lt;i>Gsdmd&lt;sup>−/−&lt;/sup>&lt;/i> mice, when challenged with LPS or TNF-α, still secreted IL-1β and IL-18, indicating inflammasome activation independent of GSDMD. Accordingly, &lt;i>Gsdmd&lt;sup>−/−&lt;/sup>&lt;/i> macrophages failed to secrete IL-1β and undergo pyroptosis when briefly exposed to NLRP3 inflammasome activators but released these cytokines when persistently activated. Sustained NLRP3 inflammasome induced caspase-8/-3 and GSDME cleavage and IL-1β maturation in vitro in &lt;i>Gsdmd&lt;sup>−/−&lt;/sup>&lt;/i> macrophages. Thus, a salvage inflammatory pathway involving caspase-8/-3–GSDME was activated after NLRP3 activation when the canonical NLRP3-GSDMD signaling was blocked. Consistent with genetic data, the active metabolite of FDA-approved disulfiram CuET, which inhibited GSDMD and GSDME cleavage in macrophages, reduced the severe inflammation and tissue damage that occurred in the &lt;i>Nlrp3&lt;sup>CA/+&lt;/sup>&lt;/i> mice. Thus, NLRP3 inflammasome activation overwhelms the protection afforded by GSDMD deficiency, rewiring signaling cascades through mechanisms that include GSDME to propagate inflammation.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2025-04-18T16:34:17.729Z</modification><creation>2025-04-07T03:50:20.759Z</creation></dates><accession>S-EPMC8780201</accession><cross_references><pubmed>34678046</pubmed><doi>10.1126/sciimmunol.abj3859</doi></cross_references></HashMap>